Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers
Executive Summary
Shared REMS, diverse confirmatory trials and manufacturing delays are among the highlights in the latest US FDA drug approval news from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Priority Review Vouchers: Majority Of US FDA Expediting Tokens Remain Unused
With Ipsen's recent approval of palovarotene, there have now been an estimated 65 priority review vouchers issued by the US FDA since the scheme started in 2007. Only 25 vouchers have been claimed, and the PVRs do not expire and can be sold, but the price appears to have peaked in 2015. Our infographic offers details on this regulatory mechanism.
Pfizer Touts Elrexfio’s Potential For Community Oncology Use In Myeloma
The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.
J&J Hits Another Myeloma Milestone With FDA Approval Of Talvey
The approval gives the company’s products a key presence in the myeloma space from the point of diagnosis and into later lines of disease.